Royal Bank of Canada
BBIO icon

Royal Bank of Canada’s BridgeBio Pharma BBIO Stock Holding History

Royal Bank of Canada’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.7M Buy
237,832
+95,425
+67% +$6.68M ﹤0.01% 1648
2026
Q1 		$10.6M Sell
142,407
-3,468
-2% -$251K ﹤0.01% 1875
2025
Q4 		$11.2M Sell
145,875
-192,534
-57% -$12.6M ﹤0.01% 1848
2025
Q3 		$17.6M Buy
338,409
+165,740
+96% +$8.08M ﹤0.01% 1747
2025
Q2 		$7.46M Buy
172,669
+165,071
+2,173% +$6M ﹤0.01% 2251
2025
Q1 		$263K Sell
7,598
-5,836
-43% -$197K ﹤0.01% 4499
2024
Q4 		$368K Sell
13,434
-6,871
-34% -$178K ﹤0.01% 4317
2024
Q3 		$517K Buy
20,305
+1,613
+9% +$42.3K ﹤0.01% 4075
2024
Q2 		$473K Buy
18,692
+11,564
+162% +$316K ﹤0.01% 4057
2024
Q1 		$221K Sell
7,128
-32,879
-82% -$1.12M ﹤0.01% 4605
2023
Q4 		$1.61M Buy
40,007
+20,748
+108% +$623K ﹤0.01% 3247
2023
Q3 		$507K Sell
19,259
-2,042
-10% -$57.9K ﹤0.01% 4018
2023
Q2 		$367K Sell
21,301
-5,953
-22% -$89.6K ﹤0.01% 4192
2023
Q1 		$452K Buy
27,254
+7,010
+35% +$81.7K ﹤0.01% 3942
2022
Q4 		$153K Buy
20,244
+6,098
+43% +$58.4K ﹤0.01% 5112
2022
Q3 		$141K Sell
14,146
-6,660
-32% -$69.2K ﹤0.01% 5060
2022
Q2 		$189K Buy
20,806
+100
+0.5% +$836 ﹤0.01% 4836
2022
Q1 		$210K Sell
20,706
-12,462
-38% -$128K ﹤0.01% 5041
2021
Q4 		$553K Buy
33,168
+24,523
+284% +$1.04M ﹤0.01% 4360
2021
Q3 		$405K Sell
8,645
-496
-5% -$26.6K ﹤0.01% 4526
2021
Q2 		$557K Sell
9,141
-117
-1% -$6.68K ﹤0.01% 4171
2021
Q1 		$570K Buy
9,258
+7,999
+635% +$523K ﹤0.01% 4069
2020
Q4 		$89K Buy
+1,259
New +$60.7K ﹤0.01% 5396
2020
Q3 		– Sell
-69
Closed -$2K – 6614
2020
Q2 		$2K Sell
69
-282
-80% -$8.59K ﹤0.01% 6266
2020
Q1 		$10K Sell
351
-887
-72% -$27.5K ﹤0.01% 5821
2019
Q4 		$43K Buy
1,238
+1,084
+704% +$30.1K ﹤0.01% 5517
2019
Q3 		$3K Buy
+154
New +$4.26K ﹤0.01% 6177

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Royal Bank of Canada's BBIO Position: Q2 2026 in Review

Royal Bank of Canada increased its BridgeBio Pharma (BBIO) stake by 67% in Q2 2026, buying an estimated $6.68M and bringing the position to 237,832 shares worth $17.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1648.

Royal Bank of Canada first reported a position in BBIO in Q3 2019 and has held it in 27 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Royal Bank of Canada held 237,832 shares of BridgeBio Pharma worth $17.7M as of Q2 2026.
  • Royal Bank of Canada bought 95,425 BridgeBio Pharma shares in Q2 2026, an estimated $6.68M.
  • BridgeBio Pharma made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #1648 holding.
  • Royal Bank of Canada first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 27 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.